Cromakalim does not act as a calcium antagonist in isolated human mesenteric artery cells.
The effects of cromakalim and its active enantiomer BRL 38226 on voltage-gated Ca2+ channels in smooth muscle cells isolated from human mesenteric arteries were studied using the whole cell patch-clamp technique. Neither of these drugs affected the Ca2+ channel current in these cells. These results suggest that the efficacy of cromakalim in lowering blood pressure in human beings does not involve a Ca2+ channel antagonistic effect.
Smirnov
S V
SV
Department of Pharmacology, United Medical School of Guy's Hospital, London, UK.
Aaronson
P I
PI
Russell
S N
SN
D001578:Benzopyrans / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D015220:Calcium Channels / Q000502:physiology; D002478:Cells, Cultured; D019806:Cromakalim; D006801:Humans; D015640:Ion Channel Gating / Q000502:physiology; D008564:Membrane Potentials / Q000187:drug effects; D008638:Mesenteric Arteries / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D011758:Pyrroles / Q000494:pharmacology*; D013237:Stereoisomerism; D014665:Vasodilator Agents / Q000494:pharmacology*
D001578:Benzopyrans; D002121:Calcium Channel Blockers; D015220:Calcium Channels; D011758:Pyrroles; D014665:Vasodilator Agents; D019806:Cromakalim